Phase 2
Completed N=15
Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C
Source: ClinicalTrials.gov NCT00621296 ↗Enrolled (actual)
15
Serious AEs
6.7%
Results posted
Oct 2012
Primary outcomePrimary: Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration — 1 participants
Summary
The purpose of this study is to assess the efficacy and safety after administration of MP-424 to patients with chronic hepatitis C.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration |
1 | — |
Eligibility Criteria
Inclusion Criteria
- Patients diagnosed with genotype 1b chronic hepatitis C
- Patients naive to the concomitant medications with interferon
Exclusion Criteria
- Patients diagnosed with decompensated cirrhosis
- Patients diagnosed with positive HBs antigen in the test
Data sourced from ClinicalTrials.gov (NCT00621296). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.